1. Home
  2. SFST vs ALT Comparison

SFST vs ALT Comparison

Compare SFST & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SFST
  • ALT
  • Stock Information
  • Founded
  • SFST 1999
  • ALT 1997
  • Country
  • SFST United States
  • ALT United States
  • Employees
  • SFST N/A
  • ALT N/A
  • Industry
  • SFST Major Banks
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • SFST Finance
  • ALT Health Care
  • Exchange
  • SFST Nasdaq
  • ALT Nasdaq
  • Market Cap
  • SFST 335.4M
  • ALT 292.0M
  • IPO Year
  • SFST 1999
  • ALT N/A
  • Fundamental
  • Price
  • SFST $44.94
  • ALT $3.54
  • Analyst Decision
  • SFST Buy
  • ALT Strong Buy
  • Analyst Count
  • SFST 1
  • ALT 6
  • Target Price
  • SFST $51.00
  • ALT $17.40
  • AVG Volume (30 Days)
  • SFST 24.9K
  • ALT 2.8M
  • Earning Date
  • SFST 10-21-2025
  • ALT 08-12-2025
  • Dividend Yield
  • SFST N/A
  • ALT N/A
  • EPS Growth
  • SFST 58.48
  • ALT N/A
  • EPS
  • SFST 2.69
  • ALT N/A
  • Revenue
  • SFST $102,878,000.00
  • ALT $20,000.00
  • Revenue This Year
  • SFST $6.08
  • ALT N/A
  • Revenue Next Year
  • SFST $13.23
  • ALT $346,228.97
  • P/E Ratio
  • SFST $16.62
  • ALT N/A
  • Revenue Growth
  • SFST 15.60
  • ALT N/A
  • 52 Week Low
  • SFST $29.14
  • ALT $2.90
  • 52 Week High
  • SFST $45.99
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • SFST 67.24
  • ALT 39.37
  • Support Level
  • SFST $41.10
  • ALT $3.51
  • Resistance Level
  • SFST $42.40
  • ALT $3.78
  • Average True Range (ATR)
  • SFST 1.12
  • ALT 0.18
  • MACD
  • SFST 0.11
  • ALT 0.05
  • Stochastic Oscillator
  • SFST 98.89
  • ALT 35.84

About SFST Southern First Bancshares Inc.

Southern First Bancshares Inc is a bank holding company. The company engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer and mortgage loans to the general public of which a majority of the revenue is derived from the Commercial and Retail Banking segment which includes the provision of traditional deposit and lending products and services to its commercial and retail banking clients.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: